Trials of Diabetes Drug Aleglitazar Scrapped

8225

After a phase III study that showed no reduction in cardiovascular events for those with diabetes, continued trials for the diabetes drug Aleglitazar have been scrapped.
The results were revealed at the 2014 American College of Cardiology Scientific Sessions.

Previous studies had showed reductions in A1c, triglycerides and LDL, or “bad” cholesterol, while raising levels of good cholesterol.

The current phase, however, while revealing a reduction in A1c levels as well as cholesterol, failed to have an impact on cardiovascular events, leading the Swiss drug maker, Roche, to terminate this and all further studies of the drug.

In addition to showing no cardiovascular benefits, the drug – a peroxisome proliferator-activated receptor agonist – has been associated with an increased risk of hypoglycemia, bone fractures, renal abnormalities and cardiovascular.

Drugs in this class have also been linked to an increased risk of cancer.

Click here to view/write comments
Diabetes Health Medical Disclaimer
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.